CRISPR Therapeutics AG
CRSPHealthcare|Biotechnology|Switzerland
$48.44
-0.71 (-1.44%)
Tangible Book
$20.04
Clinical Trials (17)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05329649 Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) | Sickle Cell Disease, Hydroxyurea Failure | P3 | Active | 13 | Open-label | CTX001 |
| NCT05356195 Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | Beta-Thalassemia, Thalassemia | P3 | Active | 16 | Open-label | CTX001 |
| NCT05565248 An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D | Diabetes Mellitus, Diabetes Mellitus, Type 1 | P1P2 | Recruiting | 40 | Open-label | — |
| NCT05643742 A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | B-cell Lymphoma, Non-Hodgkin Lymphoma | P1P2 | Recruiting | 120 | Open-label | CTX112 |
| NCT07491172 A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | Cardiovascular, Metabolic Disease | P1 | Recruiting | 90 | Open-label | CTX310 |
| NCT06925542 A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | SLE (Systemic Lupus), Lupus Erythematosus, Systemic | P1 | Recruiting | 80 | Open-label | CTX112 |
| NCT03745287 A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease | Sickle Cell Disease, Hematological Diseases | P2P3 | Completed | 63 | Open-label | CTX001 |
| NCT03655678 A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia | Beta-Thalassemia, Thalassemia | P2P3 | Completed | 59 | Open-label | CTX001 |
| NCT04208529 A Long-term Follow-up Study in Participants Who Received CTX001 | Beta-Thalassemia, Thalassemia | P3 | By Invite | 160 | Open-label | CTX001 |
| NCT04035434 A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) | B-cell Malignancy, Non-Hodgkin Lymphoma | P1P2 | Terminated | 93 | Open-label | CTX110 |
| NCT05795595 A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | Clear Cell Renal Cell Carcinoma, Cervical Carcinoma | P1P2 | Completed | 19 | Open-label | CTX131 |
| NCT06492304 A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | T Cell Lymphoma, B Cell Lymphoma | P1P2 | Completed | 12 | Open-label | CTX131 |
| NCT05210530 An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D | Diabetes Mellitus, Diabetes Mellitus, Type 1 | P1 | Completed | 7 | Open-label | — |
| NCT04244656 A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | P1 | Terminated | 26 | Open-label | CTX120 |
| NCT04438083 A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) | Renal Cell Carcinoma | P1 | Terminated | 19 | Open-label | CTX130 |
| NCT04502446 A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | T Cell Lymphoma | P1 | Terminated | 49 | Open-label | CTX130 |
| NCT06208878 A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies | Hematologic Malignancy, Solid Malignancy | By Invite | 70 | — | — |